Blood-based extracellular matrix biomarkers are correlated with clinical outcome after PD-1 inhibition in patients with metastatic melanoma

Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients

(2020) Daan P. Hurkmans et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer

(2020) Daan P. Hurkmans et al.   Journal for ImmunoTherapy of Cancer

Granzyme B Degraded Type IV Collagen Products in Serum Identify Melanoma Patients Responding to Immune Checkpoint Blockade

(2020) Christina Jensen et al.   Cancers

Collagens and Cancer associated fibroblasts in the reactive stroma and its relation to Cancer biology

(2019) Neel I. Nissen et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Anti-PD-L1 treatment results in functional remodeling of the macrophage compartment

(2019) Huizhong Xiong et al.   CANCER RESEARCH

Deep Mining of Complex Antibody Phage Pools Generated by Cell Panning Enables Discovery of Rare Antibodies Binding New Targets and Epitopes

(2019) Anne Ljungars et al.   Frontiers in Pharmacology

Collagen fragments quantified in serum as measures of desmoplasia associate with survival outcome in patients with advanced pancreatic cancer

(2019) Nicholas Willumsen et al.   Scientific Reports

Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers

(2018) Muhammad Umair Mushtaq et al.   Journal for ImmunoTherapy of Cancer

Predictive and on-treatment monitoring biomarkers in advanced melanoma: Moving toward personalized medicine

(2018) Ahmad Tarhini et al.   CANCER TREATMENT REVIEWS

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

(2018) Sanjeev Mariathasan et al.   NATURE

TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure

(2018) Ankur Chakravarthy et al.   Nature Communications

Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients

(2018) Christina Jensen et al.   Journal for ImmunoTherapy of Cancer

Elements of cancer immunity and the cancer–immune set point

(2017) Daniel S. Chen et al.   NATURE

PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity

(2017) Sydney R. Gordon et al.   NATURE

Melanoma-associated fibroblasts decrease tumor cell susceptibility to NK cell-mediated killing through matrix-metalloproteinases secretion

(2017) Linda Ziani et al.   Oncotarget

Why target the tumor stroma in melanoma?

(2017) James Hutchenreuther et al.   Journal of Cell Communication and Signaling

Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review

(2017) Charissa A. C. Jessurun et al.   Frontiers in Oncology

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

(2016) Benjamin Weide et al.   CLINICAL CANCER RESEARCH

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Granzyme B Promotes Cytotoxic Lymphocyte Transmigration via Basement Membrane Remodeling

(2014) Monica D. Prakash et al.   IMMUNITY

Post-translational modifications of the extracellular matrix are key events in cancer progression: Opportunities for biochemical marker development

(2011) D. J. Leeming et al.   BIOMARKERS

Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer

(2011) T. R. Cox et al.   Disease Models & Mechanisms

Matrix Metalloproteinases: Regulators of the Tumor Microenvironment

(2010) Kai Kessenbrock et al.   CELL

Novel combinations of Post-Translational Modification (PTM) neo-epitopes provide tissue-specific biochemical markers—are they the cause or the consequence of the disease?

(2010) Morten Asser Karsdal et al.   CLINICAL BIOCHEMISTRY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER